A phase Ib safety and pharmacokinetic study of ARQ 501 [beta-lapachone] in combination with docetaxel in adult patients with locally advanced or metastatic carcinoma

Trial Profile

A phase Ib safety and pharmacokinetic study of ARQ 501 [beta-lapachone] in combination with docetaxel in adult patients with locally advanced or metastatic carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2008

At a glance

  • Drugs Beta lapachone; Docetaxel
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Mar 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
    • 07 Aug 2006 Status change
    • 19 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top